Home > Insights > boult.bites Biotech – Winter 2014

Authors: Joanna Peak , Jennifer O’Farrell , Edward Ronan and David Wortley
13 February, 2014

The end of 2013 saw a flurry of activity in the SPC world as the CJEU handed down its judgements in cases C-484/12 (Georgetown University v Octrooicentrum Nederland), C-443/12(Actavis Group v Sanofi) and C-493/12 (Eli Lilly v HGS). These decisions have been eagerly awaited, because the referrals to the court addressed two key issues: (I) can a Patentee obtain more than one SPC per patent and (II) what is a “product protected by a basic patent in force” under Article 3(a) of Regulation No. 469/2009 (the SPC Regulation).

PDF icon Download the PDF

Authors

joanna peak

Joanna Peak
Partner

Phone this number (0)+44 20 7430 7500

Email this address jpeak@boult.com

Verulam Gardens
70 Gray's Inn Road
London
WC1X 8BT

Jennifer O'Farrell

Jennifer O’Farrell
Partner

Phone this number (0)+44 20 7430 7500

Email this address jo'farrell@boult.com

Verulam Gardens
70 Gray's Inn Road
London
WC1X 8BT

Edward Ronan

Edward Ronan
Patent Attorney

Phone this number (0)+44 20 7430 7500

Email this address eronan@boult.com

Verulam Gardens
70 Gray's Inn Road
London
WC1X 8BT

David Wortley

David Wortley
Patent Attorney

Phone this number (0)+44 1223 883000

Email this address dwortley@boult.com

CPC4 Capital Park
Cambridge Road
Cambridge
CB21 5XE